



Policy Name: Long-Acting Opioid Prior Authorization Policy

Start Date: 4/1/19

Required Medical Information

- Members who have opioids prescribed for pain associated with a cancer diagnosis, terminal condition, or pain being managed through hospice or palliative care shall have access to the medication.
- The prescriber attests that Rhode Island's regulations for Pain Management, Opioid Use and the Registration of Distributors of Controlled Substances are being followed.
- The prescriber attests that they will use or are using an objective tool to monitor the member's pain.
- The prescriber attests and acknowledges that the risk of serious harm is markedly increased with concurrent use of benzodiazepines (BZD) and other Central Nervous System (CNS) depressants.
- The prescriber attests that the patient has a prescription for or is in possession of naloxone.
- The prescriber attests that they have counseled the patient (and patient cohabitants, if available) on how to obtain and administer naloxone.
- The prescriber attests to understanding the findings of the CDC's Guideline for Prescribing Opioids for Chronic Pain (2016, 2017) which include:
 - 1) long term opioid therapy is associated with increased risk for serious harm including opioid use disorder, overdose, and death;
 - 2) risk of harm increases with dosage;
 - 3) opioids pose risk to all patients and currently available tools cannot rule out risk for opioid use disorder or other serious harm;
 - 4) evidence for clinical benefit of long term opioid therapy is insufficient
- The patient has tried and failed the following alternatives for the treatment of pain:
 - non-pharmacologic therapy and
 - non-opioid therapy and
 - non-pharmacologic therapy and/or non-opioid therapy in combination with a low dose opioid.

New starts

- The requested drug is being prescribed for pain severe enough to require daily, around-the-clock, long-term treatment in a patient who has been taking an opioid (not opioid naïve).

Renewal Criteria

- The original opioid dosing has been titrated down from the initial authorization or in the prescribers clinical opinion it is inappropriate to decrease the dose for this member.

Quantity Limit/MME (Opioid being prescribed over the FDA recommended dose or over 90 MME)

- The patient has tried and failed non pharmacologic therapy and non opioid therapy to treat their pain AND has tried non pharmacologic therapy and/or non opioid therapy in combination with a LOW DOSE opioid.
- The prescriber attests to understanding the findings of the CDC's Guideline for Prescribing Opioids for Chronic Pain (2016, 2017) which concluded that long term opioid therapy is associated with increased risk for serious harm (opioid use disorder, overdose, & death) in a dose-dependent manner: **≥ 50 MME** significantly increases risk for harm & indicates need to reassess; **≥ 90 MME** sharply increases risk for harm & requires justification of risk; **≥ 200 MME** is associated with Over Dose (OD) death

Non-formulary

- The patient has tried and failed 3 formulary alternatives, or formulary alternatives would not be appropriate (contraindication, adverse effect, etc.).

Approvals: All approvals x 1 year.



Policy Name: Long-Acting Opioid Prior Authorization Policy

Start Date: 4/1/19

Providers seeking dosages over the Post Quantity Limits below need to provide Neighborhood with documentation as to why such dosages are necessary.

Opioid Analgesics Quantity Limits Chart

The duration of 25 days is used for a 30-day fill period to allow time for refill processing. Limits are set up as quantity versus time edits.

| | Authorization Limit (Post Limit QL) |
|----------------------|--|
| Drug/Strength | <u>Number of Tablets per 25 days</u> that should be entered on the authorization. Limit is either 200 MME/day or FDA Max Dose, whichever is less. Example: MS Contin 200 mg 30 tablets per 30 days has a limit of 200 MME per day (Approvals above 200 MME/day are based on Clinical Judgment) |
| Arymo ER 15 mg | 120 tabs (60 MME/day) |
| Arymo ER 30 mg | 120 tabs (120 MME/day) |
| Arymo ER 60 mg | 100 tabs (200 MME/day) |
| Avinza 30 mg | 60 caps (60 MME/day) |
| Avinza 45 mg | 60 caps (90 MME/day) |
| Avinza 60 mg | 60 caps (120 MME/day) |
| Avinza 75 mg | 60 caps (150 MME/day) |
| Avinza 90 mg | 60 caps (180 MME/day) |
| Avinza 120 mg | 50 caps (200 MME/day) |
| Belbuca 75 mcg | 90 films (6.75 MME/day) |
| Belbuca 150 mcg | 90 films (13.5 MME/day) |
| Belbuca 300 mcg | 90 films (27 MME/day) |
| Belbuca 450 mcg | 90 films (40.5 MME/day) |
| Belbuca 600 mcg | 90 films (54 MME/day) |
| Belbuca 750 mcg | 90 films (67.5 MME/day) |
| Belbuca 900 mcg | 90 films (81 MME/day) |
| Butrans 5 mcg/hr | 8 patches (18 MME/day) |
| Butrans 7.5 mcg/hr | 8 patches (27 MME/day) |
| Butrans 10 mcg/hr | 8 patches (36 MME/day) |



Policy Name: Long-Acting Opioid Prior Authorization Policy

Start Date: 4/1/19

| | |
|--------------------|------------------------------|
| Butrans 15 mcg/hr | 8 patches (54 MME/day) |
| Butrans 20 mcg/hr | 8 patches (72 MME/day) |
| Conzip 100 mg | 60 caps (20 MME/day) |
| Conzip 200 mg | 60 caps (40 MME/day) |
| Conzip 300 mg | 60 caps (60 MME/day) |
| Dolophine 5 mg | 120 tabs (80 MME/day) |
| Dolophine 10 mg | 90 tabs (120 MME/day) |
| Duragesic 12 mcg | 20 patches (57.6 MME/day) |
| Duragesic 25 mcg | 20 patches (120 MME/day) |
| Duragesic 37.5 mcg | 20 patches (180 MME) |
| Duragesic 50 mcg | 17 patches (200 MME/day) |
| Duragesic 62.5 mcg | 13 patches (200 MME/day) |
| Duragesic 75 mcg | 11 patches (200 MME/day) |
| Duragesic 87.5 mcg | 10 patches (200 MME/day) |
| Duragesic 100 mcg | 8 patches (200 MME/day) |
| Embeda 20/0.8 mg | 90 caps (60 MME/day) |
| Embeda 30/1.2 mg | 90 caps (90 MME/day) |
| Embeda 50/2 mg | 90 caps (150 MME/day) |
| Embeda 60/2.4 mg | 90 caps (180 MME/day) |
| Embeda 80/3.2 mg | 75 caps (200 MME/day) |
| Embeda 100/4 mg | 60 caps (200 MME/day) |
| Exalgo 8 mg | 60 tabs (64 MME/day) |
| Exalgo 12 mg | 60 tabs (96 MME/day) |
| Exalgo 16 mg | 60 tabs (128 MME/day) |
| Exalgo 32 mg | 47 tabs (200 MME/day) |
| Hysingla ER 20 mg | 60 tabs (40 MME/day) |
| Hysingla ER 30 mg | 60 tabs (60 MME/day) |
| Hysingla ER 40 mg | 60 tabs (80 MME/day) |
| Hysingla ER 60 mg | 60 tabs (120 MME/day) |
| Hysingla ER 80 mg | 60 tabs |



Policy Name: Long-Acting Opioid Prior Authorization Policy

Start Date: 4/1/19

| | |
|----------------------------------|--|
| | (160 MME/day) |
| Hysingla ER 100 mg | 60 tabs (200 MME/day) |
| Hysingla ER 120 mg | 50 tabs (200 MME/day) |
| Kadian 10 mg | 90 caps (30 MME/day) |
| Kadian 20 mg | 90 caps (60 MME/day) |
| Kadian 30 mg | 90 caps (90 MME/day) |
| Kadian 40 mg | 90 caps (120 MME/day) |
| Kadian 50 mg | 90 caps (150 MME/day) |
| Kadian 60 mg | 90 caps (180 MME/day) |
| Kadian 70 mg | 86 caps (200 MME/day) |
| Kadian 80 mg | 75 caps (200 MME/day) |
| Kadian 100 mg | 60 caps (200 MME/day) |
| Kadian 130 mg | 46 caps (200 MME/day) |
| Kadian 150 mg | 40 caps (200 MME/day) |
| Kadian 200 mg | 30 caps (200 MME/day) |
| Methadone 10 mg/mL Intensol soln | 150 mL (200 MME/day) |
| Methadone 5 mg/5 mL Oral soln | 600 mL (80 MME/day) |
| Methadone 10 mg/5 mL Oral soln | 600 mL (160 MME/day) |
| Methadone 200 mg/20 mL inj | 40 mL (2 multidose vials) (53.3 MME/day) |
| Methadone 5 mg | 120 tabs (80 MME/day) |
| Methadone 10 mg | 90 tabs (120 MME/day) |
| MorphaBond ER 15 mg | 120 tabs (60 MME/day) |
| MorphaBond ER 30 mg | 120 tabs (120 MME/day) |
| MorphaBond ER 60 mg | 100 tabs (200 MME/day) |
| MorphaBond ER 100 mg | 60 tabs (200 MME/day) |
| MS Contin 15 mg | 120 tabs (60 MME/day) |
| MS Contin 30 mg | 120 tabs (120 MME/day) |
| MS Contin 60 mg | 100 tabs (200 MME/day) |
| MS Contin 100 mg | 60 tabs (200 MME/day) |
| MS Contin 200 mg | 30 tabs |



Policy Name: Long-Acting Opioid Prior Authorization Policy

Start Date: 4/1/19

| | |
|-------------------------|---------------------------|
| | (200 MME/day) |
| Nucynta ER 50 mg | 90 tabs (60 MME/day) |
| Nucynta ER 100 mg | 90 tabs (120 MME/day) |
| Nucynta ER 150 mg | 90 tabs (180 MME/day) |
| Nucynta ER 200 mg | 75 tabs (200 MME/day) |
| Nucynta ER 250 mg | 60 tabs (200 MME/day) |
| Opana ER 5 mg | 90 tabs (45 MME/day) |
| Opana ER 7.5 mg | 90 tabs (67.5 MME/day) |
| Opana ER 10 mg | 90 tabs (90 MME/day) |
| Opana ER 15 mg | 90 tabs (135 MME/day) |
| Opana ER 20 mg | 90 tabs (180 MME/day) |
| Opana ER 30 mg | 67 tabs (200 MME/day) |
| Opana ER 40 mg | 50 tabs (200 MME/day) |
| OxyContin 10 mg | 90 tabs (45 MME/day) |
| OxyContin 15 mg | 90 tabs (67.5 MME/day) |
| OxyContin 20 mg | 90 tabs (90 MME/day) |
| OxyContin 30 mg | 90 tabs (135 MME/day) |
| OxyContin 40 mg | 90 tabs (180 MME/day) |
| OxyContin 60 mg | 67 tabs (200 MME/day) |
| OxyContin 80 mg | 50 tabs (200 MME/day) |
| Targiniq ER 10 mg/5 mg | 90 tabs (45 MME/day) |
| Targiniq ER 20 mg/10 mg | 90 tabs (90 MME/day) |
| Targiniq ER 40 mg/20 mg | 90 tabs (180 MME/day) |
| Tramadol ER 100 mg | 60 tabs (20 MME/day) |
| Tramadol ER 200 mg | 60 tabs (40 MME/day) |
| Tramadol ER 300 mg | 60 tabs (60 MME/day) |
| Troxyca ER 10 mg/1.2 mg | 90 caps (45 MME/day) |
| Troxyca ER 20 mg/2.4 mg | 90 caps (90 MME/day) |
| Troxyca ER 30 mg/3.6 mg | 90 caps (135 MME/day) |
| Troxyca ER 40 mg/4.8 mg | 90 caps (180 MME/day) |



Policy Name: Long-Acting Opioid Prior Authorization Policy

Start Date: 4/1/19

| | |
|-------------------------|---------------------------|
| Troxyca ER 60 mg/7.2 mg | 67 caps (200 MME/day) |
| Troxyca ER 80 mg/9.6 mg | 50 caps (200 MME/day) |
| Ultram ER 100 mg | 60 tabs (20 MME/day) |
| Ultram ER 200 mg | 60 tabs (40 MME/day) |
| Ultram ER 300 mg | 60 tabs (60 MME/day) |
| Vantrela ER 15 mg | 90 tabs (45 MME/day) |
| Vantrela ER 30 mg | 90 tabs (90 MME/day) |
| Vantrela ER 45 mg | 90 tabs (135 MME/day) |
| Vantrela ER 60 mg | 90 tabs (180 MME/day) |
| Vantrela ER 90 mg | 67 tabs (200 MME/day) |
| Xtampza ER 9 mg | 90 caps (45 MME/day) |
| Xtampza ER 13.5 mg | 90 caps (67.5 MME/day) |
| Xtampza ER 18 mg | 90 caps (90 MME/day) |
| Xtampza ER 27 mg | 90 caps (135 MME/day) |
| Xtampza ER 36 mg | 90 caps (180 MME/day) |
| Zohydro ER 10 mg | 90 caps (30 MME/day) |
| Zohydro ER 15 mg | 90 caps (45 MME/day) |
| Zohydro ER 20 mg | 90 caps (60 MME/day) |
| Zohydro ER 30 mg | 90 caps (90 MME/day) |
| Zohydro ER 40 mg | 90 caps (120 MME/day) |
| Zohydro ER 50 mg | 90 caps (150 MME/day) |